Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.70 |
| ▸ | PGR | P06401 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | SHBG | P04278 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326003 | 0.87 | ESR1 (0.78) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL349803 | 0.87 | ESR1 (0.78) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL17318121 | 0.86 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL19096138 | 0.86 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL6872679 | 0.86 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL19123270 | 0.86 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL4395173 | 0.86 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| Ethinyl Estradiol SCHEMBL26659950 | 0.85 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL8931573 | 0.85 | ESR1 (0.74) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL4389365 | 0.85 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889727-B1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-03-08 | — | — | EP | claimed |
| EP-0889727-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-13 | — | — | EP | claimed |
| WO-1997033589-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | claimed |
| US-20120225853-A1 | HORMONE REPLACEMENT THERAPY AND DEPRESSION | Bayer Pharma AG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-7629334-B1 | treating hormone deficiency and hormone irregularity symptoms; free of estrogen, no cancer side effect; [4-[17 beta Methoxy-17 alpha -(methoxymethyl)-3-oxoestra-4,9-dien-11 beta -yl]benzaldehyd-(1E)-oxim] | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-08 | — | — | US | disclosed |
| EP-1635843-B1 | THERAPY COMPRISING DIENOGEST FOR HORMONE REPLACEMENT AND DEPRESSION | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| EP-1605924-B1 | MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF COMPOSITIONS FOR HORMONE REPLACEMENT THERAPY (HRT) | BAYER SCHERING PHARMA AG (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1635843-A1 | THERAPY COMPRISING DIENOGEST FOR HORMONE REPLACEMENT AND DEPRESSION | Schering AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1423407-B1 | 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | SCHERING AG (DE) | 2006-03-08 | — | — | EP | disclosed |
| EP-0889727-B1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1605949-A2 | MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF FEMALE CONTRACEPTIVES | Schering Aktiengesellschaft (DE) | 2005-12-21 | — | — | EP | disclosed |
| WO-2001034126-A9 | MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF COMPOSITIONS FOR HORMONE REPLACEMENT THERAPY (HRT) | JENAPHARM GMBH (DE) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002019971-A9 | 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GMBH (DE) | 2002-08-08 | — | — | WO | disclosed |
| US-20020091112-A1 | 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | US | disclosed |
| WO-2002019971-A1 | 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GMBH & CO. KG (DE) | 2002-03-14 | — | — | WO | disclosed |
| EP-1150662-A1 | LAMINATES CONTAINING AN ACTIVE SUBSTANCE FOR TRANSDERMAL SYSTEMS | Jenapharm GmbH & Co. KG (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001026603-A2 | MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF FEMALE CONTRACEPTIVES | JENAPHARM GMBH & CO. KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000047191-A1 | LAMINATES CONTAINING AN ACTIVE SUBSTANCE FOR TRANSDERMAL SYSTEMS | JENAPHARM GMBH & CO. KG (DE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0889727-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997033589-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091112-A1 | 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds | CYP17A1, HSD17B11, CYP19A1 | ESR1 59/4885LMNA 2466/4885NR3C1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.